An official website of the United States government
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Omalizumab (Xolair): Treatment of Adults and Adolescents (12 Years of Age and above) with Chronic Idiopathic Urticaria [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug.
| Drug | omalizumab (Xolair) (150 mg and 300 mg subcutaneous injection) |
|---|---|
| Indication | Treatment of adults and adolescents (12 years of age and above) with chronic idiopathic urticaria who remain symptomatic despite H1 antihistamine treatment |
| Listing request | Treatment of adults and adolescents (12 years of age and above) with persistent (disease duration ≥ 6 months) moderate to severe (UAS7 score ≥ 16 or DLQI ≥ 10) chronic idiopathic urticaria who remain symptomatic (presence of hives and/or associated itching) despite H1-antihistamine treatment. |
| Manufacturer | Novartis Pharmaceuticals Canada Inc. |
APPENDIX 1 PATIENT INPUT SUMMARY
APPENDIX 2 LITERATURE SEARCH STRATEGY
APPENDIX 4 DETAILED OUTCOME DATA
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Your browsing activity is empty.
Activity recording is turned off.
See more...
